Dose Rounding and Available Formulations

From a simulated dose to a deliverable regimen

A model-derived dose is not automatically a usable prescription. A calculation may identify 375 mg once daily as a promising dose, while the available tablets, measurable liquid volumes, vial policies, or infusion equipment permit only a small set of actual regimens. The practical decision is therefore not just how to round a number. It is whether a feasible regimen, administered as intended, retains an acceptable balance of efficacy and safety in the population of interest.

The central rule is simple: after translating the proposed dose into the available formulation and administration instructions, simulate that regimen itself. Do not assume that a small numerical change has a small clinical effect. That assumption may fail when exposure is nonlinear in dose, concentrations lie near a target boundary, or the schedule changes.

For a fixed schedule and route, let \(d^*\) be the model-derived dose and let \(\mathcal{D}\) be the set of doses that can be administered. A simple numerical rounding rule selects the feasible dose closest to \(d^*\). But the clinically suitable choice may instead need to satisfy efficacy and safety requirements. For example, define \(P_E(d)\) as the simulated probability of meeting an efficacy target at dose \(d\), and \(P_S(d)\) as the simulated probability of exceeding a safety limit. If the minimum acceptable efficacy probability is \(q_E\) and the maximum acceptable safety probability is \(q_S\), the acceptable feasible doses are:

This set may contain several doses or none. When it contains more than one, a decision rule is needed—for example, choosing the dose nearest \(d^*\) among acceptable doses, or applying a prespecified benefit-risk or operational criterion. When it is empty, do not label a merely rounded dose acceptable. Reconsider the formulation, schedule, or clinical criteria with appropriate clinical and regulatory input.

What “rounding” means in practice

Available formulations impose different kinds of constraints. A tablet may allow only whole or scored units; a liquid formulation may be measurable only to a specified volume increment; a vial may allow partial withdrawal but be subject to single-use or preparation rules; an infusion may impose a deliverable concentration and pump-rate range. These details determine \(\mathcal{D}\). A vial’s labeled amount is not necessarily the administered dose: if partial withdrawal is permitted, a vial can supply several possible doses. Conversely, a policy requiring a whole vial for one administration may restrict the feasible doses sharply.

For a tablet strength \(s\) that must be administered in whole tablets, feasible doses are multiples of \(s\), subject to any limits on tablet splitting. For a liquid concentration \(c\) and measurable volume increment \(v\), feasible doses are multiples of \(cv\), if the entire volume is administered and the concentration is fixed. Those arithmetic rules identify candidates, but they do not say which candidate is clinically appropriate.

If the only objective were to minimize absolute dose difference, the nearest feasible dose would minimize \(|d-d^*|\). For a fixed \(d^*\), minimizing squared difference gives the same nearest candidate because squaring is increasing for nonnegative absolute differences:

This is a justification for a numerical convenience rule, not for clinical equivalence. A feasible dose that is 5 mg away can have worse target attainment than a dose 15 mg away if the dose-response relationship is steep, the schedule differs, or the candidates cross a safety boundary. Clinical criteria must therefore be evaluated after defining the actual regimen.

Simulation and interpretation

A useful comparison simulates each candidate regimen in the intended population, using the same population definition, covariate distribution, model assumptions, efficacy endpoint, and safety endpoint used to assess the proposed dose. For each simulated individual, calculate whether the efficacy target is met and whether the safety limit is exceeded. With \(N\) simulated individuals, the estimated efficacy target-attainment probability is the number meeting the efficacy target divided by \(N\); the estimated safety probability is defined analogously.

These are simulation estimates, not guarantees for future patients. Their Monte Carlo variability depends on \(N\). For an estimated probability \(\hat p\) from \(N\) simulated individuals, an approximate Monte Carlo standard error is \(\sqrt{\hat p(1-\hat p)/N}\). This quantifies simulation noise under the specified model and simulation setup; it does not include uncertainty from an incorrect model, uncertain parameters, or an unrepresentative population.

When comparing candidates, using the same simulated individuals and random-effect draws can make comparisons less noisy because the outcomes are paired by virtual individual. The marginal attainment estimate for each dose is still calculated as above. Interpret differences with care: a small difference may reflect Monte Carlo variation rather than a meaningful change, especially when the simulation is small or the estimate is close to a decision threshold.

When the schedule or formulation changes

A dose amount cannot always be rounded independently of frequency, duration, or administration method. For drugs with nonlinear pharmacokinetics, the exposure change from a dose change may not be proportional to the amount change. Even with linear pharmacokinetics, changing the interval can alter peak and trough concentrations and therefore affect efficacy or safety endpoints. A liquid volume, tablet count, vial policy, or infusion rate may make a different schedule more practical, but any schedule change creates a different regimen to simulate.

Diagnostics, alternatives, and limitations

Before using a rounded-regimen result, check that the simulated inputs describe the regimen that can actually be delivered. Important failure modes include using the nominal dose instead of the rounded dose in the simulation, applying the wrong liquid concentration, treating a vial label as an administered dose when partial withdrawal is allowed, overlooking a tablet-splitting restriction, and changing the interval without updating the simulation. Check that the simulated population and covariates still match the decision population, and that efficacy and safety endpoints have the intended definitions and units.

Inspect the pattern across feasible candidates rather than relying on one rounded point. A sudden or counterintuitive change in attainment can indicate a steep dose-response region, a schedule effect, a coding or unit error, or Monte Carlo noise. If neighboring candidates give unexpectedly different results, verify the dose conversion and simulation inputs, then increase the simulation size or use paired simulations where appropriate. A larger simulation reduces Monte Carlo error but cannot repair an incorrect model or population.

Resimulation is only as relevant as its assumptions. A model may not represent formulation-dependent absorption, food effects, preparation loss, infusion duration, adherence, or real-world administration errors unless these are explicitly incorporated. The selected regimen should also be robust enough for the intended setting; a simulated estimate barely above a threshold warrants more scrutiny than a result comfortably meeting it. Numerical proximity to the model-derived dose is not a substitute for clinical judgment or a prespecified decision rule.